EGFR and lung carcinoma: Advances in treatment have resulted in survival prolongation among patients with lung cancer, but this has resulted in a corresponding increase in the incidence of LMC.9 The incidence of LMC among patients with non‐small cell lung cancer (NSCLC) has been previously reported to be 3%–5%,10 and LMC more frequently occurs in patients with EGFR mutations (in up to 20% of patients) than in patients with EGFR wild type.11 The main challenge in treating LMC is poor penetration of chemotherapeutic agents through the blood‐brain barrier.